8-K: Vivani Medical Advances GLP-1 Implants, Secures Funding

Vivani Medical reports Q3 2025 financial results, announces plans for Phase 1 semaglutide implant study in H1 2026, and secures $25.7 million in financing.

Summary

• Vivani Medical successfully completed LIBERATE-1, the first clinical application of its NanoPortal platform technology.
• The company plans to initiate a Phase 1 clinical study for NPM-139, a semaglutide implant for chronic weight management, in the first half of 2026.
• Parallel investments are being made to enable rapid initiation of a Phase 2 dose-ranging study for NPM-139, pending Phase 1 results and regulatory feedback.
• Preclinical data for NPM-139 demonstrated 20% weight loss sustained over more than 7 months.
• Vivani secured approximately $25.7 million in cash and cash commitments through a Q3 2025 private placement and October financings, extending its financial position into 2027.
• The planned spin-off of Cortigent, Inc., a wholly owned subsidiary, was temporarily withdrawn due to the U.S. federal government shutdown, with a new record date expected after the SEC resumes normal operations.
• Net loss for Q3 2025 increased to $6.5 million, compared to $6.0 million in Q3 2024.
• Cash, cash equivalents, and restricted cash totaled $4.0 million as of September 30, 2025, down from $19.7 million as of December 31, 2024, prior to the recent financings.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While Q3 financial results show increased losses and reduced cash (pre-financing), the significant capital raise provides a strong runway into 2027. The clinical progress with the NanoPortal platform and promising preclinical data for NPM-139 in a high-demand market (GLP-1 for obesity) are strong positives, despite the minor delay in the Cortigent spin-off.

Positives

• Successful completion of the LIBERATE-1 clinical study, validating the NanoPortal platform technology.
• Strong preclinical data for NPM-139 showing 20% weight loss sustained over 7+ months.
• Secured approximately $25.7 million in cash and cash commitments, providing financial runway into 2027.
• Vivani is uniquely positioned as the only company developing ultra long-acting miniature GLP-1 implants for onceor twice-yearly dosing.
• The NanoPortal platform aims to address critical challenges in obesity treatment: poor medication adherence and tolerability.

Negatives

• Net loss increased to $6.5 million for Q3 2025, up from $6.0 million in Q3 2024.
• Cash, cash equivalents, and restricted cash decreased to $4.0 million as of September 30, 2025, from $19.7 million at December 31, 2024, before the recent capital raises.
• The planned spin-off of Cortigent, Inc. was temporarily delayed due to the U.S. federal government shutdown.

Risks

• Risks related to the development and commercialization of Vivani's products.
• Potential delays and changes in product development due to laws, regulations, guidelines, or regulatory clearance/approval.
• Risks associated with the initiation, enrollment, and conduct of planned clinical trials and their results.
• Vivani's history of losses and its ability to access additional capital or otherwise fund its business.
• Risks that the Cortigent spin-off may not be completed in a timely manner or at all.
• Risks of failure to satisfy any conditions required for the Cortigent spin-off.
• Risks that the Cortigent spin-off may not qualify for non-recognition of gain or loss for U.S. federal income tax purposes.
• Uncertainty regarding whether the anticipated benefits of the Cortigent spin-off can be achieved.
• Risks of unexpected costs or delays in business operations.
• Risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies, and objectives.
• Market conditions and Cortigent's ability to complete its spin-off, fund its business, and advance its product candidates and pre-clinical programs.

Future Outlook

Vivani anticipates initiating clinical development of its semaglutide implant, NPM-139, for obesity and chronic weight management in the first half of 2026, pending regulatory clearance. The company also expects to complete the spin-off of its subsidiary, Cortigent, as an independent publicly traded company shortly after the SEC resumes normal operations.

Management Comments

• Vivani achieved significant progress during the third quarter of 2025, including the successful completion of LIBERATE-1, marking the first clinical application of the Company's proprietary platform technology, NanoPortal.
• The LIBERATE-1 study paves the way for continued development of our growing pipeline of ultra long-acting miniature drug implants, including NPM-139 and NPM-133, our semaglutide-based implants in development for chronic weight management and treatment of type 2 diabetes, respectively.
• Our initial focus is on the Phase 1 study, which we anticipate will generate clinical data supporting both semaglutide development programs.
• Vivani remains the only company developing ultra long-acting miniature GLP-1 implants designed for onceor twice-yearly dosing.
• Our NanoPortal drug delivery platform is uniquely differentiated from a competitive landscape that includes over 50 injectable and oral candidates in development for chronic weight management by offering both infrequent administration and peace of mind that, if necessary, treatment can be discontinued at any time.
• NanoPortal GLP-1 implants promise to address two of the main challenges in obesity treatment today that contribute to suboptimal patient outcomes: poor medication adherence and poor tolerability.
• We are excited to be positioned to initiate clinical development of the semaglutide implant program in the first half of 2026.

Industry Context

Vivani Medical operates in the highly competitive metabolic disease market, specifically targeting obesity and type 2 diabetes with its GLP-1 based implants. The company positions its NanoPortal platform as uniquely differentiated from over 50 injectable and oral candidates by offering ultra long-acting, onceor twice-yearly dosing with the ability to discontinue treatment, aiming to improve medication adherence and tolerability, which are significant challenges in current obesity treatments.

Comparison to Industry Standards

• Vivani's NanoPortal drug delivery platform is differentiated from a competitive landscape that includes over 50 injectable and oral candidates in development for chronic weight management.
• The company's GLP-1 implants are designed for onceor twice-yearly dosing, offering infrequent administration compared to daily or weekly oral and injectable medications.
• The implants provide the ability to discontinue treatment at any time, which is a unique feature compared to other long-acting therapies.

Legal Proceedings

• A litigation accrual of $1.675 million is reported on the balance sheet as of September 30, 2025.

Related Party Transactions

• An entity affiliated with Gregg Williams, the Chairman of the Company's board of directors, purchased 3,703,703 shares of common stock at $1.62 per share in a concurrent private placement on October 28, 2025.
• An entity beneficially owned by Gregg Williams was one of two investors in a private placement on August 11, 2025, for 7,936,507 shares of common stock at $1.26 per share.

Stakeholder Impact

• Shareholders: Experience dilution from recent capital raises but benefit from extended financial runway and accelerated pipeline development. The Cortigent spin-off delay introduces uncertainty.
• Patients: Potential for novel, ultra long-acting GLP-1 implants (NPM-139, NPM-133) to address medication adherence and tolerability issues in obesity and type 2 diabetes.
• Employees: Continued employment and focus on advancing clinical programs due to secured financing.
• Creditors: Improved financial stability due to significant capital raise, reducing immediate liquidity concerns.

Next Steps

• Initiate a Phase 1 clinical study of NPM-139 (semaglutide implant for chronic weight management) in the first half of 2026, pending regulatory clearance.
• Initiate a Phase 2 clinical study of NPM-139, pending enabling results from the Phase 1 study and regulatory feedback.
• Establish a new record date for the spin-off of Cortigent, Inc. shortly after the U.S. Securities and Exchange Commission resumes normal operations.

Key Dates

Recommendation

Vivani Medical presents a mixed but strategically positive outlook. The significant capital raise of $25.7 million, securing operations into 2027, is a crucial de-risking event for a development-stage biotech. The progress with the NanoPortal platform, successful LIBERATE-1 study, and promising preclinical data for NPM-139 in the high-growth GLP-1 market are strong long-term positives. However, the increased net loss for Q3 2025 and the temporary delay in the Cortigent spin-off introduce near-term uncertainties. While the long-term potential is attractive given the unique drug delivery technology, the stock carries inherent risks associated with clinical development and regulatory approvals. A 'hold' recommendation reflects the balance between these promising developments and the ongoing financial burn and execution risks, suggesting investors monitor clinical trial progress and the successful completion of the Cortigent spin-off.

Keywords

GLP-1 implants, semaglutide, obesity treatment, type 2 diabetes, NanoPortal platform, biopharmaceutical, clinical trials, weight management, drug delivery, Cortigent spin-off